| NCT Number | Conditions | Interventions | Sponsor/Collaborators | Phases | Start Date | Last Updated |
| NCT01131767 | Healthy | Drug: Naproxen Sodium & Pseudoephedrine HCl | Dr. Reddy's Laboratories Limited | Phase 1 | 2004-07-01 | 2010-06-11 |
| NCT01131728 | Healthy | Drug: Naproxen Sodium & Pseudoephedrine HCl | Dr. Reddy's Laboratories Limited | Phase 1 | 2004-07-01 | 2010-06-11 |
| NCT00969449 | Pharmacokinetics | Drug: Naproxen Sodium, (BAY H6689)|Drug: Naprelan, (BAY H6689) | Bayer | Phase 1 | 2009-04-01 | 2014-05-19 |
| NCT01052129 | Healthy | Drug: Naproxen sodium | Dr. Reddy's Laboratories Limited | Phase 1 | 2006-05-01 | 2010-05-26 |
| NCT01052792 | Healthy | Drug: Naproxen Sodium | Dr. Reddy's Laboratories Limited | Phase 1 | 2006-05-01 | 2010-01-19 |
| NCT00488514 | Migraine Disorders | Drug: Combination Tablet of Treximet (sumatriptan/naproxen sodium) | GlaxoSmithKline | Phase 3 | 2007-07-01 | 2016-10-11 |
| NCT01952652 | Arthroscopic Meniscus Surgery | Drug: Group N:Naproxen sodium|Drug: Group NC :naproxen sodium codeine phosphate | Baskent University | Phase 4 | 2013-01-01 | 2013-09-26 |
| NCT01383486 | Pain | Drug: Naproxen sodium ER (BAYH6689)|Drug: Advil | Bayer | Phase 3 | 2011-07-01 | 2015-09-24 |
| NCT01389284 | Pain, Postoperative | Drug: Naproxen Sodium ER (BAYH6689)|Drug: Naproxen Sodium IR (Aleve, BAYH6689)|Drug: Naproxen Sodium ER Placebo|Drug: Naproxen Sodium IR Placebo | Bayer | Phase 3 | 2011-06-01 | 2015-08-12 |
| NCT00792636 | Migraine Disorders | Drug: sumatriptan and naproxen sodium combination tablet|Drug: sumatriptan tablet|Drug: naproxen sodium tablet | GlaxoSmithKline | Phase 4 | 2008-11-01 | 2016-10-11 |
| NCT00818415 | Pain | Drug: Naproxen sodium ER (BAYH6689)|Drug: Commercial Naproxen (Aleve, BAYH6689) | Bayer | Phase 1 | 2008-11-01 | 2014-05-16 |
| NCT00586365 | Heterotopic Ossification | Drug: Naproxen | Massachusetts General Hospital | Phase 4 | 2007-10-01 | 2012-03-20 |
| NCT01495858 | Pain, Postoperative | Drug: Naproxen Sodium 440 mg / DPH 25 mg (BAY98-7111)|Drug: Naproxen Sodium 440 mg (BAYH6689)|Drug: DPH 50 mg | Bayer | Phase 3 | 2011-12-01 | 2015-05-13 |
| NCT00720057 | Toothache | Drug: Naproxen Sodium ER (BAYH6689)|Drug: Placebo | Bayer | Phase 3 | 2008-06-01 | 2015-08-12 |
| NCT03092193 | Poor Metabolizer Due to Cytochrome P450 CYP2C9 Variant|Poor Metabolizer Due to Cytochrome p450 CYP2C19 Variant | Drug: Naproxen|Drug: Naproxen-esomeprazole | University of Sao Paulo|Fundao de Amparo Pesquisa do Estado de So Paulo | Phase 4 | 2017-03-01 | 2017-03-24 |
| NCT00966641 | Healthy Volunteers | Drug: Naproxen|Drug: PL 3100 | PLx Pharma|National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) | Phase 1|Phase 2 | 2009-08-01 | 2015-08-06 |
| NCT01280591 | Pain, Postoperative | Drug: Naproxen sodium 440 mg / DPH 50 mg (BAY98-7111)|Drug: Naproxen sodium 220 mg / DPH 50 mg (BAY98-7111)|Drug: Naproxen sodium 440 mg (BAYH6689)|Drug: DPH 50 mg | Bayer | Phase 3 | 2010-10-01 | 2015-05-13 |
| NCT02494856 | Pain|Other Surgical Procedures|Impacted Third Molar Tooth | Drug: Surgery with Naproxen|Drug: Surgery with Naproxen and Esomeprazole | Giovana Maria Weckwerth|Fundao de Amparo Pesquisa do Estado de So Paulo|University of Sao Paulo | Phase 4 | 2014-10-01 | 2016-11-03 |
| NCT02702817 | Alzheimer Disease|Cognitive Decline Due to Alzheimer Disease|Mild Cognitive Impairment Due to Alzheimer Disease | Drug: Naproxen|Drug: Placebo | Douglas Mental Health University Institute|McGill University|Johns Hopkins University | Phase 2 | 2012-08-01 | 2016-03-03 |
| NCT02229461 | Hematology | Drug: Naproxen Sodium (Aleve, BAY117031)|Drug: Acetylsalicylic Acid (Aspirin, BAYE4465) | Bayer | Phase 1 | 2015-02-01 | 2016-06-16 |
